Bausch Health Companies Inc. (BHC) Financials

NYSE:BHC

Market Cap

2.81B

Total Revenue

8.12B

Gross Profit

5.76B

Operating Income

1.37B

Net Income

-212.00M

Metric	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
revenue	5,769,605,000	8,263,500,000	10,498,800,000	9,674,000,000	8,724,000,000	8,380,000,000	8,601,000,000	8,027,000,000	8,434,000,000	8,124,000,000
costOfRevenue	1,905,120,000	2,254,600,000	2,645,000,000	2,611,000,000	2,548,000,000	2,351,000,000	2,350,000,000	2,249,000,000	2,394,000,000	2,364,000,000
grossProfit	3,864,485,000	6,008,900,000	7,853,800,000	7,063,000,000	6,176,000,000	6,029,000,000	6,251,000,000	5,778,000,000	6,040,000,000	5,760,000,000
researchAndDevelopmentExpenses	156,783,000	246,000,000	582,800,000	455,000,000	366,000,000	414,000,000	471,000,000	452,000,000	465,000,000	529,000,000
sellingAndMarketingExpenses	--	--	-17,100,000	--	--	--	--	--	--	--
generalAndAdministrativeExpenses	1,305,164,000	2,026,300,000	2,699,800,000	2,810,000,000	2,582,000,000	2,473,000,000	--	--	--	--
sellingGeneralAndAdministrativeExpenses	1,305,164,000	2,026,300,000	2,682,700,000	2,810,000,000	2,582,000,000	2,473,000,000	2,554,000,000	2,367,000,000	2,624,000,000	2,625,000,000
operatingExpenses	3,363,924,000	3,823,000,000	5,669,800,000	5,938,000,000	5,638,000,000	5,531,000,000	6,336,000,000	4,464,000,000	4,837,000,000	4,404,000,000
operatingIncome	-409,502,000	2,039,700,000	1,554,600,000	-566,000,000	102,000,000	-2,384,000,000	-73,000,000	676,000,000	1,210,000,000	1,370,000,000
totalOtherIncomeExpensesNet	-978,720,000	-127,300,000	-752,200,000	-1,732,000,000	-451,000,000	-2,978,000,000	-1,764,000,000	-1,610,000,000	-2,234,000,000	-1,499,000,000
ebitda	3,146,816,000	4,132,600,000	5,084,400,000	5,457,000,000	3,407,000,000	3,174,000,000	1,824,000,000	2,518,000,000	2,585,000,000	2,585,000,000
depreciationAndAmortization	1,901,977,000	1,550,700,000	2,404,300,000	2,673,000,000	2,858,000,000	2,644,000,000	1,897,000,000	1,842,000,000	1,375,000,000	1,215,000,000
interestIncome	8,023,000	5,000,000	3,300,000	8,000,000	12,000,000	11,000,000	12,000,000	13,000,000	7,000,000	14,000,000
interestExpense	844,316,000	971,000,000	1,563,200,000	1,836,000,000	1,840,000,000	1,685,000,000	1,612,000,000	1,534,000,000	1,426,000,000	1,464,000,000
incomeBeforeTax	-1,314,452,000	1,092,600,000	-128,100,000	-2,435,000,000	-1,741,000,000	-4,154,000,000	-1,837,000,000	-934,000,000	-1,024,000,000	-129,000,000
incomeTaxExpense	-450,783,000	180,400,000	134,200,000	-27,000,000	-4,145,000,000	-10,000,000	-54,000,000	-375,000,000	-87,000,000	83,000,000
netIncome	-866,142,000	913,500,000	-266,200,000	-2,409,000,000	2,404,000,000	-4,148,000,000	-1,783,000,000	-559,000,000	-937,000,000	-212,000,000
eps	-2.7	3.16	-0.77	-6.94	8.63	-11.86	-5.06	-1.57	-2.61	-0.59
epsdiluted	-2.7	3.1	-0.77	-6.94	8.59	-11.86	-5.06	-1.57	-2.61	-0.59
weightedAverageShsOut	320,996,000	335,400,000	347,300,000	347,300,000	350,200,000	349,871,102	352,100,000	355,000,000	358,900,000	362,000,000
weightedAverageShsOutDil	320,996,000	341,500,000	347,300,000	347,300,000	351,800,000	349,871,102	352,100,000	355,000,000	358,900,000	362,000,000
costAndExpenses	5,269,044,000	6,077,600,000	8,314,800,000	8,549,000,000	8,186,000,000	7,882,000,000	8,686,000,000	6,713,000,000	7,231,000,000	6,768,000,000
otherExpenses	-234,442,000	268,700,000	-256,100,000	-73,000,000	-1,000,000	21,000,000	3,311,000,000	1,645,000,000	1,748,000,000	1,250,000,000

Key Facts

Industry

Drug Manufacturers—Specialty & Generic

Sector

Healthcare

Headquarters

Laval, QC, CA

Website

bauschhealth.com

CEO

Mr. Thomas J. Appio

Employees

19900

About the Company

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.